Related Experiment Video
Updated: Jun 25, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Omegaven for the treatment of parenteral nutrition associated liver disease: a case study
Aaron W Calhoun1, Janice E Sullivan
1Department of Pediatrics, University of Louisville, 571 S. Floyd Street, Ste 332, Louisville, KY 40202, USA. aaron.calhoun@louisville.edu
Insights
Omegaven, an Omega-3-based lipid emulsion, successfully treated severe liver damage in an infant with Short Gut Syndrome receiving long-term parenteral nutrition. This innovative therapy resolved cholestasis and hepatopathy, potentially preventing the need for organ transplantation.
Area of Science:
- Hepatology
- Pediatric Gastroenterology
- Nutritional Science
Background:
- Infants with Short Gut Syndrome often require chronic parenteral nutrition (PN), which can lead to severe liver complications like cholestasis and hepatopathy.
- The management of PN-induced liver disease in pediatric patients presents significant challenges, sometimes necessitating multivisceral organ transplantation.
Observation:
- A 17-month-old infant with Short Gut Syndrome experienced severe cholestasis and hepatopathy secondary to long-term PN.
- Treatment with Omegaven, an experimental parenteral lipid formulation rich in Omega-3 triglycerides, was initiated to prevent organ transplantation.
Findings:
- Within six months of Omegaven administration, the infant's cholestasis resolved, and hepatopathy significantly improved.
- Omegaven's efficacy is attributed to its Omega-3 fatty acid composition, which enhances fat absorption and modulates inflammatory responses.
Implications:
- Omegaven shows promise as a therapeutic option for alleviating parenteral nutrition-induced cholestasis in infants.
- This case highlights the potential of alternative lipid emulsions in managing complex gastrointestinal and liver conditions in pediatric patients.
- Further clinical trials are warranted to establish the role of Omegaven in treating PN-associated liver disease.
Abstract:
A 17-month-old infant diagnosed with Short Gut Syndrome developed severe cholestasis and hepatopathy due to chronic parenteral nutrition (PN). In an effort to prevent multivisceral organ transplantation, he was started on Omegaven, an experimental alternative form of parenteral lipid. Within six months, his cholestasis had resolved and his hepatopathy had significantly improved. Omegaven uses Omega-3 rather than Omega-6 triglycerides as its primary fat source, improving fat absorption and modulating the systemic inflammatory response. It has also shown promise as a means of alleviating PN-induced cholestasis in several small trials. Omegaven is only available in the United States on compassionate use basis.
Related Concept Videos
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Enteral Nutrition I: Orogastric and Nasogastric Feeding
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
Kidney Transplant III: Nursing Management

